{"id":"b958fb02-4b1e-5043-8664-1f67245e88ae","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-perilla-nasal-cells","predicate":"decreases_in_recorded_comparison","statement":"Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"97c54441-75cc-5734-918b-13bdd8b17330","mechanism_event_label":"Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.","subject":{"id":"30ca7b15-db8f-5b8b-9dfc-62b04e915585","slug":"perilla-ra-enriched-extract","display_name":"RA-enriched Perilla frutescens extract","entity_type_key":"botanical"},"object":{"id":"93b30d6a-24ec-597a-b819-d3f5d8dfd360","slug":"human-nasal-lavage-inflammatory-cells","display_name":"Human nasal lavage neutrophil/eosinophil counts","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"97c54441-75cc-5734-918b-13bdd8b17330","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-perilla-nasal-cells-event","event_type":"experimental_observation","label":"Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.","description":"### ra-perilla-nasal-cells\n\nActive perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.\nNo adverse events or routine blood-test abnormalities were reported in this small trial. Oral administration did not directly bathe nasal tissue.\nModel and exposure: Same 29-patient, 21-day trial.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"30ca7b15-db8f-5b8b-9dfc-62b04e915585","slug":"perilla-ra-enriched-extract","display_name":"RA-enriched Perilla frutescens extract","entity_type_key":"botanical"},"role":"tested factor","stoichiometry":null,"state_label":"Enriched perilla extract","sequence_order":0,"notes":""},{"entity":{"id":"93b30d6a-24ec-597a-b819-d3f5d8dfd360","slug":"human-nasal-lavage-inflammatory-cells","display_name":"Human nasal lavage neutrophil/eosinophil counts","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"extract constituent","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Enriched perilla extract\", \"comparator\": \"Placebo\", \"endpoint\": \"Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Same 29-patient, 21-day trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Active perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-perilla-nasal-cells; No adverse events or routine blood-test abnormalities were reported in this small trial. Oral administration did not directly bathe nasal tissue.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"d4911b19-87c3-5a51-94f9-4e3cc5e2c48c","evidence_kind":"source_excerpt","locator":"Lines 293-299","start_line":293,"end_line":299,"excerpt":"### ra-perilla-nasal-cells\n\nActive perilla-extract treatment reduced nasal-lavage neutrophil and eosinophil counts.\nNo adverse events or routine blood-test abnormalities were reported in this small trial. Oral administration did not directly bathe nasal tissue.\nModel and exposure: Same 29-patient, 21-day trial.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. | 2004 | https://pubmed.ncbi.nlm.nih.gov/14988517/ | https://doi.org/10.1177/153537020422900305 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Same 29-patient, 21-day trial.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}